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Abstract
Attention-deficit hyperactivity disorder (ADHD) is a common disorder that is associated with
broad functional impairment among both children and adults. The purpose of this paper is to review
and summarize available literature on the economic costs of ADHD, as well as potential economic
benefits of treating this condition. A literature search was performed using MEDLINE to identify all
published articles on the economic implications of ADHD, and authors were contacted to locate
conference abstracts and articles in press that were not yet indexed. In total, 22 relevant items
were located including published original studies, economic review articles, conference
presentations, and reports available on the Internet. All costs were updated and presented in terms
of year 2004 US dollars. A growing body of literature, primarily published in the United States, has
demonstrated that ADHD places a substantial economic burden on patients, families, and third-
party payers. Results of the medical cost studies consistently indicated that children with ADHD
had higher annual medical costs than either matched controls (difference ranged from $503 to
$1,343) or non-matched controls (difference ranged from $207 to $1,560) without ADHD. Two
studies of adult samples found similar results, with significantly higher annual medical costs among
adults with ADHD (ranging from $4,929 to $5,651) than among matched controls (ranging from
$1,473 to $2,771). A limited number of studies have examined other economic implications of
ADHD including costs to families; costs of criminality among individuals with ADHD; costs related
to common psychiatric and medical comorbidities of ADHD; indirect costs associated with work
loss among adults with ADHD; and costs of accidents among individuals with ADHD. Treatment
cost-effectiveness studies have primarily focused on methylphenidate, which is a cost-effective
treatment option with cost-effectiveness ratios ranging from $15,509 to $27,766 per quality-
adjusted life year (QALY) gained. As new treatments are introduced it will be important to evaluate
their cost-effectiveness to provide an indication of their potential value to clinicians, patients,
families, and third-party payers.
Introduction
Attention-deficit hyperactivity disorder (ADHD) is charac-
terized by a persistent and developmentally inappropriate
pattern of inattention, hyperactivity, and/or impulsivity
[1]. Children with ADHD tend to have difficulty organiz-
ing tasks and sustaining attention during schoolwork or
play activities. Typical disruptive behaviors include failing
to remain seated, talking excessively, playing noisily, and
blurting out answers before questions have been com-
pleted. ADHD is relatively common, with prevalence rates
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among school-age children in the United States ranging
from roughly 4% to 12%, depending on the diagnostic
approach [2-4]. Furthermore, the percentage of children
treated for ADHD in the United States increased dramati-
cally from the 1980s to the 1990s [5,6].
ADHD is associated with impairment in many areas of
children's lives, including academic performance, social
functioning, and overall quality of life [7-12]. Children
with ADHD are frequently rejected by their peers as early
as the first day of contact, likely as a result of their ten-
dency toward disruptive and aggressive behavior [13].
ADHD also has long-term negative outcomes for many
children, including decreased educational attainment,
work performance, and occupational stability compared
to individuals without ADHD [14,15].
Because of the broad impact of ADHD, the disorder is
likely to have serious economic implications for children,
families, and society. Research has only recently begun to
examine these economic costs, but the initial studies sug-
gest that ADHD leads to increased costs in healthcare and
other domains. The purpose of this paper is to review and
summarize available literature on the economic costs of
ADHD, as well as potential economic benefits of treating
this condition. In addition, recommendations for addi-
tional research on the economic implications of ADHD
are provided.
Methods
A literature search was performed using MEDLINE,
accessed through PubMed, to identify all published arti-
cles on the economic implications of ADHD. Searches
were conducted using both the term and medical subject
heading "ADHD" (in addition to the full term "attention-
deficit/hyperactivity disorder" as well as individual words
including "attention" and "hyperactivity"), along with
economic terms including "cost," "costs," "economic,"
and "economics." Reference sections of relevant articles,
including one review article that summarized eight eco-
nomic studies [16], were reviewed to identify additional
studies that may not have been included in MEDLINE.
Finally, authors were contacted to locate conference
abstracts and articles in press that were not yet indexed. In
total, 22 relevant items were located including published
original studies, unpublished conference presentations,
and reports available on the Internet. Articles that dis-
cussed resource use patterns for ADHD but did not attach
costs to these patterns [17] are not included in this review.
All costs were updated to year 2004 US dollars based on
the medical component of the Consumer Price Index [18].
Results
Direct Medical Costs of ADHD in Children and 
Adolescents
Formal cost of illness studies measure the "economic"
burden resulting from disease and illness across a defined
population (e.g., patients in the US), including both
direct medical costs and indirect (e.g., lost productivity)
costs [19]. Although no formal cost of illness estimates
incorporating both direct and indirect costs of ADHD
have been published, several studies have presented esti-
mates of the direct medical costs of treating children and
adolescents with ADHD (see Table 1). In three of the stud-
ies [20-22], annual costs of care for children with ADHD
were compared to annual costs for matched (on age and
sex) controls. Three other studies included a similar com-
parison, but utilized non-matched controls [23-25]. Stud-
ies by Chan et al. [26] and Kelleher et al. [27] compared
treatment costs for childhood ADHD with childhood
asthma. Leslie et al. [28] examined trends over time in
costs for children with ADHD, and Marchetti et al. [29]
compared costs by type of ADHD treatment. Birnbaum et
al. [30] used the data set previously analyzed by Swensen
et al. [21,22] to estimate total excess costs for the US pop-
ulation, defined as the difference between ADHD patients
and matched controls.
A majority of the medical cost studies used insurance
claims data from private insurers [20-22,28,30], from
state Medicaid agencies [25,27], or from both sources
[23,24]. The cost estimates reported by Chan et al. [26]
were based on nationally representative household survey
data, while the study by Marchetti et al. [29] relied on lit-
erature review and clinical expert opinion. The time
period for the health care resource data used in the various
studies ranged from 1987 to 1998.
The results of the medical cost studies were consistent in
indicating that children with ADHD had higher annual
medical costs than either matched controls (difference
ranged from $503 to $1,343) or non-matched controls
(difference ranged from $207 to $1,560) without ADHD
(Table 1). The higher costs for ADHD patients were due to
increased use of hospitalizations, primary care office vis-
its, outpatient mental health visits, and pharmacy fills. For
example, children with ADHD were 9.02 and 8.75 times
more likely than other children (matched on age and sex)
to have outpatient mental health visits and pharmacy fills,
respectively [20]. When compared with cohorts of chil-
dren with asthma (who were more likely to be female and
African-American), children with ADHD had slightly
higher annual treatment costs; but the differences were
not statistically significant [26,27]. When Birnbaum and
colleagues [30] used claims data to estimate excess costs of
ADHD across the US population, the excess ADHD-
related treatment costs were $0.53 billion for girls andCost Effectiveness and Resource Allocation 2005, 3:5 http://www.resource-allocation.com/content/3/1/5
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Table 1: Studies of the Direct Costs of ADHD
Citation Sample Data Sources (Time Period) Findings1
Birnbaum et al. 2005 Treated ADHD patients aged 7–44 
(N = 1219) and their family 
members under age 65 (N = 
3692); controls without ADHD 
matched to both patients (N = 
1219) and family members (N = 
3692) on age, gender, employment 
status, geographical location age, 
gender, state of residence, and 
employment status)
Claims data from large Fortune 
100 company (1996–1998)
This study estimated total excess costs for the 
US population, defined as the difference between 
ADHD patients/family members and controls. 
Annual mean direct ADHD treatment costs 
(2004 US $) were $674/$745 for girls/boys with 
ADHD (excess costs = $0.53/$1.06 billion) and 
$412/$529 for female/male adults with ADHD 
(excess costs = $0.13/$0.40 billion). Annual 
other direct treatment costs (2004 US $) were 
$865/$990 for girls/boys (excess costs = $0.80/
$2.0 billion) and $2609/$3022 for female/male 
adults with ADHD (excess costs = $0.67/$1.46 
billion).
Burd et al. 2003a Children aged 0–21 years with 
ADHD (N = 3,872) and non-
matched controls (N = 95,119) 
without ADHD
North Dakota Health Claims 
Database (1996–1997)
Annual, mean direct treatment costs (2004 US $) 
were $870 for ADHD patients versus $663 for 
controls; 1.9% of total annual health 
expenditures in North Dakota attributable to 
ADHD.
Chan et al. 2002 Children aged 5–20 years with 
ADHD (N = 165), asthma (N = 
322) or neither diagnosis (N = 
4,952)
Nationally representative 
household survey data (1996)
Annual, incremental direct treatment costs 
(2004 US $) were $661 for children with ADHD 
(P < 0.001) and $603 for children with asthma (P 
< 0.01) (relative to costs for children with 
neither diagnosis)
Guevara et al. 2001 Children aged 3–17 years with 
ADHD (N = 2992) and matched 
(on age and sex) controls (N = 
11,968) without ADHD
Health maintenance organization 
in western Washington State 
(1997)
Annual, incremental direct treatment costs 
(2004 US $) were $503 (95% CI: $450–552) for 
children with ADHD alone and $1088 (95% CI: 
$899–$1,304) for children with ADHD plus 
coexisting mental health disorders (relative to 
costs for children with no ADHD)
Kelleher et al. 2001 Children aged 7–20 years with 
ADHD (N = 1,602) and with 
asthma (N = 1,411)
Medicaid claims data for patients in 
Pittsburgh, PA and surrounding 
counties (1994–1995)
Annual, mean (± SD) direct treatment costs 
(2004 US $) were $2,567 ± $2,959 for the 
ADHD group versus $2,382 ± $2,664 for the 
asthma group (difference not statistically 
significant)
Leibson et al. 2001 Children aged 5–19 years with 
ADHD (N = 309) and non-
matched controls (N = 3,810) 
without ADHD
Rochester, Minnesota medical 
facility-linked billing data system 
(1987–1995)
Long-term (9 year), median direct treatment 
costs (2004 US $) for ADHD patients compared 
with those without ADHD were more than 
double ($6,158 vs. $2,780; P < 0.001), even for 
the subset with no hospital or emergency room 
admissions ($183 vs. $93; P < 0.001)
Leslie et al. 2001 Children aged ≤ 17 years with use 
of mental health services, including 
patients with hyperactivity 
(N~10,000)
Health care claims for privately 
insured population (MarketScan®) 
(1993–1996)
Annual inpatient costs (2004 US $) per treated 
hyperactive patient declined from $26,550 in 
1993 to $8,644 in 1996 (P < 0.001); there was 
also a significant decline in outpatient treatment 
costs ($931 and $659, respectively, P < 0.001)
Mandell et al. 2003 Children aged 3–15 years with 
ADHD (N = 4,306) and with no 
psychiatric disorder (N = 60,975)
Medicaid claims data for patients in 
Philadelphia, PA (1993–1996)
Long-term (3 year), mean direct treatment costs 
(2004 US $) were $4,891 for ADHD patients 
versus $221 for patients with no psychiatric 
disorder
Marchetti et al. 2001 Hypothetical cohort of school-
aged children with ADHD
Literature review, managed care 
survey, clinical experts (2000–
2001)
Average, total annual expected cost (2001 US $) 
per treated patient was $1,710 for Metadate CD, 
$1876 for Concerta, $2,061 for methylphenidate 
immediate-release/extended release (MPH IR/
ER), $2,122 for MPH IR, $2,392 for Ritalin, and 
$2,567 for Adderall.
Secnik et al. 2005b Adults aged 18–64 with ADHD (N 
= 2,252) and matched controls 
without ADHD (N = 2252; 
matched on age, gender, 
metropolitan statistical area, and 
type of insurance coverage)
Health care claims for privately 
insured population (MarketScan®) 
(1999–2001)
Controlling for the impact of comorbidities, 
adults diagnosed with ADHD had significantly (P 
< 0.0001) higher outpatient costs ($3,009 vs. 
$1.491), inpatient costs ($1,259 vs. $514), 
prescription drug costs ($1,673 vs. $1,008) and 
total annual medical costs ($5,651 vs. $2,771) 
compared with matched controls without 
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$1.06 billion for boys, and the excess overall healthcare
costs were $0.80 billion for girls and $2.00 billion for
boys.
Marchetti et al. [29] examined the costs of six different
ADHD drug therapies: generic and branded (Ritalin)
MPH immediate release (IR) therapies, two branded MPH
extended release (ER) therapies (Concerta and Metadate
CD), generic MPH IR/ER, and a combination therapy of
amphetamine salts (Adderall). The annual expected cost
of treatment with each drug therapy, including costs
incurred with physician visits and lab exams, was highest
for Adderall at $2,567 (2004 US $) and lowest for Meta-
date CD at $1,710. The cost for the other therapies ranged
from $2,061 (Concerta) to $2,392 (Ritalin).
Direct Medical Costs of ADHD in Adults
Although ADHD is often perceived as a disorder of child-
hood and adolescence, there is growing awareness that
many children continue to demonstrate symptoms in
adulthood, although many adults with ADHD remain
undiagnosed and untreated [31]. Limited prevalence data
on adult ADHD are available, but estimates generally
indicate that 30% to 70% of children with ADHD con-
tinue to have symptoms in adulthood [32,33]. Adult
symptom presentation is likely to be somewhat different
from the common symptoms of childhood, with less
hyperactivity, but with continued problems with organi-
zational tasks and distractibility. ADHD is known to have
a broad range of negative outcomes for adults, including
relatively high rates of criminality, poor job performance,
lower occupational status, problems in social skills, poor
driving records, and comorbid psychiatric disorders
[14,15,34].
Despite the continuing impact of ADHD in adulthood,
only three studies were located that examined economic
costs of adults with ADHD (Table 1) [22,30,35]. Secnik et
al. and Swensen et al. compared costs of care for adults
with ADHD with matched controls (matched on age, sex,
metropolitan statistical area, and type of insurance cover-
age), and both utilized privately insured claims data for
the analysis. The two studies both indicated that adults
with ADHD have significantly higher annual medical
costs (ranging from $4,929 to $5,651) than matched con-
trols (ranging from $1,473 to $2,771), even after control-
ling for patient comorbidity [35]. Birnbaum and
colleagues used the same sample as Swensen et al. to esti-
mate total excess costs for adults in the US population
(i.e., the difference between ADHD patients and matched
controls). The excess ADHD-related treatment costs were
$0.13 billion for women and $0.40 billion for men, and
the excess overall healthcare costs were $4.79 billion for
women and $8.51 billion for men.
Costs to Families
The relationship between children and their families is
complex and bi-directional, involving simultaneous
mutual influence [36,37]. Children are shaped by their
experiences with parents, while simultaneously influenc-
ing their parents' behavior and emotions [38,39]. This
mutual influence between parents and children has been
well-documented among families with a child who has
been diagnosed with ADHD. Family environment and
parent-child interaction has been shown to be a key causal
factor in the development of ADHD and related conduct
problems in longitudinal studies [40]. Conversely, the
symptoms of ADHD have profound effects not only on
the child, but also on the child's parents. For example,
children's ADHD is frequently linked with strain in the
Swensen et al. 2003 Children aged 0–18 years with 
ADHD (N = 1,086) and matched 
(on age, gender, and state of 
residence) controls (N = 1,086) 
without ADHD
Claims data from large Fortune 
100 company (1996–1998)
Annual, mean (± SD) direct treatment costs 
(2004 US $) were $2,046 ± $3,474 for the 
ADHD group versus $703 ± $2,215 for matched 
controls without ADHD (P < 0.0001).
Swensen et al. 2004 Individuals aged 0–64 with ADHD 
(N = 1,308) and matched (on age, 
gender, state of residence, and 
employment status) controls (N = 
1,308) without ADHD
Claims data from large Fortune 
100 company (1996–1998)
Annual, mean direct treatment costs (2004 US $) 
were $1,797 for children with ADHD versus 
$577 for matched controls without ADHD (P < 
0.05); $2,230 for adolescents with ADHD versus 
$783 for matched controls without ADHD (P < 
0.05); and $4,929 for adults with ADHD versus 
$1,473 for matched controls without ADHD (P 
< 0.05).
1All costs updated to Year 2004 US $ using the Medical Services component of the Consumer Price Index (for US-based studies). For non-US 
studies, all country-specific costs first updated to Year 2004 currency values based on country-specific inflators; and then converted to Year 2004 
US$ based on currency exchange rates.
MPH = methylphenidate
IR = immediate release
ER = extended release
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parent-child relationship, disturbance in parents' marital
functioning (e.g., less marital satisfaction and more con-
flict than parents of children without ADHD), and
extremely high parental stress [40,41].
A recent study conducted by Swensen and colleagues [21]
suggests that childhood ADHD also places an economic
burden on parents and other family members. This analy-
sis was conducted using 1996–1998 data from a national
sample of over 100,000 beneficiaries of a large US com-
pany that include industrial, service, and professional
employees. Family members of individuals affected with
ADHD had 1.6 times as many medical claims as matched
control individuals without a family member diagnosed
with ADHD (matching based on age, gender, geographi-
cal location, and employment status). This greater health-
care utilization resulted in increased costs. Annual direct
per-capita medical costs were twice as much for family
members of ADHD patients ($2,740) than for family
members of control patients ($1,365). Indirect costs
related to disability and absenteeism followed a similar
pattern (family members of ADHD patients, $888; family
members of controls, $551). Birnbaum et al. [30] used the
same data set to estimate excess healthcare costs across the
US population (i.e., the difference between family mem-
bers of ADHD patients and family members of matched
controls), which were $6.78 billion for family members of
children with ADHD and $12.10 billion for family mem-
bers of adults with ADHD.
There are several possible reasons for the higher indirect
costs of parents whose children have ADHD. For example,
children with ADHD are likely to require energy and
attention that might otherwise be focused on work-related
responsibilities. Furthermore, these parents may often be
required to miss work in order to meet with teachers or
take their children to appointments with physicians or
mental health professionals. These high indirect costs sug-
gest that ADHD has a financial impact not only on family
members, but also on employers who might be affected
by family members increased disability and absenteeism.
A nationally representative US survey conducted in 1998
suggests that mothers of children with ADHD perceive the
financial impact of their children's disorder [42]. Com-
pared with mothers whose children were not diagnosed
with ADHD, mothers of children with ADHD were 3.3
times as likely to say that the family could not afford pre-
scription medication for the child and 7.4 times as likely
to say the family could not afford mental-health care for
the child. Another study of parent perceptions clearly
demonstrates the substantial economic burden of ADHD
[43]. In this study, parents were asked whether they per-
ceive their child's hyperactivity as a serious problem. The
strongest predictor of whether parents considered ADHD
to be a serious problem was the financial impact related
to work, defined as the impact of the child's behavior on
either parent's employment patterns or chances of a career
(e.g., leaving work to pick up the child). Compared with
parents who did not think ADHD was a serious problem,
parents who perceived their child's ADHD to be a serious
problem were 17.6 times more likely to say that there
child's ADHD had a financial impact related to their work.
Taken together, Swensen's study of family medical costs
and these two studies of parent perceptions indicate that
ADHD has a substantial impact on family finances.
Given the impact of a child's ADHD on parents' absentee-
ism and productivity, it may be beneficial for employers
and human resource specialists to consider strategies for
minimizing this impact. A recent survey of 41 employers
in four American cities found that the participants knew
little about ADHD prevalence or its potential effects on
parents, despite their responsibility for purchasing
employees' health insurance [44]. However, employers
did offer several benefits and policies that could be help-
ful to parents whose children have ADHD, including on-
site parent training programs, assistance with child care,
flexible work/leave policies, and referral services that
linked parents with community programs. When asked
about benefits that could be targeted specifically for fam-
ilies of children with ADHD, employers suggested lunch
seminars about ADHD and flexible hours for employees
to meet with schools or physicians. As employers gain
greater awareness of the economic impact of ADHD, it is
hoped that such programs and benefits may be imple-
mented at more companies.
Costs of Criminality
Several longitudinal studies have shown that childhood
ADHD is associated with criminality in adolescence and
adulthood. For example, a study conducted in Los Angeles
found that children diagnosed with ADHD between the
ages of 6 and 12 years old had significantly higher juvenile
(46% versus 11%) and adult (21% versus 1%) arrest rates
compared to normal control subjects [45]. A similar study
conducted in New York found that children with ADHD
were more likely than controls to later be arrested (39%
versus 20%), convicted (28% versus 11%), and incarcer-
ated (9% versus 1%) [46]. Another study, conducted with
17–18 year old adolescents in San Francisco, found that
the ADHD group was more likely than the control group
to be on probation, in jail, or assigned to a social worker
by the court [47].
One study has estimated the economic impact of crimi-
nality associated with ADHD [48]. Data were from a sam-
ple of children (4–12 years old) identified in 1979 and
1980. Follow-up interviews were conducted between
1991 and 1996 with 149 children diagnosed with ADHDCost Effectiveness and Resource Allocation 2005, 3:5 http://www.resource-allocation.com/content/3/1/5
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and 76 control children when a sample ranged in age
from 19 to 25 years. Criminal history was assessed
through self-report, including crimes (e.g., stealing,
assault), juvenile detention, probation, and jail. The costs
of crimes incurred by victims and costs to the criminal jus-
tice system were estimated based on information from the
Bureau of Justice Statistics, the Federal Bureau of Investi-
gation, and the Criminal Justice Institute. Compared with
the control group, the ADHD patients were more than
twice as likely to have been arrested (48% versus 20%).
The mean total criminal costs were dramatically greater
for ADHD patients than for controls ($12,868 versus
$498). All differences were statistically significant.
Although this study should be considered a rough esti-
mate, findings strongly suggest that criminality associated
with ADHD results in a significant cost to society.
Costs of Comorbidities
Children with ADHD tend to have elevated rates of other
psychiatric conditions [21,49,50] For example, about
30% of children with ADHD meet criteria for an anxiety
disorder, compared to about 10% of the general popula-
tion. Behavioral problems such as conduct disorder and
oppositional defiant disorder are particularly common
among children with ADHD, with comorbid rates of
roughly 50%. Other conditions that are commonly
comorbid with ADHD include learning disabilities,
depression, and possibly bipolar disorder. When estimat-
ing the impact of ADHD, it is important to consider these
comorbidities because comorbid conditions can influ-
ence children's long-term course and response to
treatment.
One study has estimated the incremental increase in costs
of treatment for ADHD with comorbid conditions, com-
pared with treatment of ADHD alone [51]. Analyses were
conducted using 1996 and 1997 data from the North
Dakota Department of Health's Claims Database. Gener-
ally, comorbid psychiatric disorders substantially
increased the costs of treating children with ADHD. For
example over the two years, comorbid depression
increased costs by an average of $358 per patient per year.
Increases were also observed with oppositional defiant
disorder ($258), bipolar disorder ($541), conduct disor-
der ($488), anxiety ($499), nondependent drug use
($868), tics ($198), and personality disorders ($247).
Non-psychiatric medical disorders also resulted in
increased costs, including respiratory illness ($630), acute
sinusitis ($670), general injuries ($972), and allergies
($507).
In the North Dakota sample, the only comorbid condi-
tions that were associated with lower costs compared to
children without comorbid conditions were learning dis-
abilities (-$759) and epilepsy (-$777). However, another
recent study focusing on comorbid epilepsy in an admin-
istrative claims database from 1998 to 2001 found con-
trasting results [52]. In a sample, the average annual
treatment costs for children with ADHD and comorbid
epilepsy were $5,194, compared with $4,246 for children
with ADHD but not epilepsy. Despite the mixed results
relating to learning disabilities and epilepsy, initial find-
ings suggest that the common comorbid conditions of
ADHD may contribute to elevated treatment costs among
this population.
Costs of Accidents
Children with ADHD have been shown to be more acci-
dent prone than other children [53], likely because of
their tendencies toward impulsive, overactive behavior.
They are also more likely than other children to experi-
ence injuries due to accidents, such as broken bones, lac-
erations, head injuries, bruises, lost teeth, or accidental
poisonings [54,55]. One study has estimated the inci-
dence and cost of accidents among individuals with
ADHD using an administrative database of medical, phar-
maceutical, and disability claims for national manufactur-
ers' employees, spouses, dependents, and retirees [22].
Analyses were conducted for the whole population, adults
alone, children under age 12, and adolescents aged 12 to
18 years. ADHD patients in all age groups were more
likely than a matched control group to have at least one
accident claim: children, 28% versus 18%; adolescents,
32% versus 23%, and adults, 38% versus 18%. Among
adults, the accident-specific direct medical costs were sig-
nificantly higher among ADHD patients than among the
control group ($642 versus $194). Among children and
adolescents, there were not significant differences in acci-
dent-specific costs between the ADHD groups and the
control groups.
Costs of Work Loss
ADHD is associated with work-related problems in adult-
hood such as poor job performance, lower occupational
status, less job stability, and increased absence days in
comparison to adults without ADHD [15,34,35,56]. This
poor performance and work loss is likely to have pro-
found economic implications. One study quantified this
impact by estimating the excess costs (i.e., the difference
between adult ADHD patients and matched controls)
related to work loss [30]. Indirect work loss costs were cal-
culated based on employer payments for disability claims
and imputed wages for medically-related work absence
days (e.g., days in the hospital, physician visits). The
excess costs were $1.20 billion for women with ADHD
and $2.26 billion for men with ADHD.
Cost-Effectiveness of Treatments for ADHD
Three published studies have utilized decision analytic
modeling techniques to assess the cost-effectiveness ofCost Effectiveness and Resource Allocation 2005, 3:5 http://www.resource-allocation.com/content/3/1/5
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drug therapy (i.e. methylphenidate [MPH]) for ADHD
[57-59] (see Table 2). Each of these studies represented
"complete" economic evaluations (i.e. estimated both the
incremental costs and incremental effects associated with
treatment). In two of the studies [57,58], the effectiveness
of treatment was measured in terms of "quality-adjusted
life years" (QALYs), an outcome measure that incorpo-
rates quality of life benefits and time [60]. These quality of
life benefits are quantified using utility scores, which have
been shown to be feasible and valid for assessment of chil-
dren with ADHD [61-63]. In the third study [59], treat-
ment effectiveness was based on gains in the Conners
Teacher Rating Scale, a commonly used teacher-report
questionnaire for assessing children's classroom behavior
[64].
Overall, results of the three modeling analyses indicate
that MPH is a cost-effective treatment option for children
with ADHD. The cost per QALY gained in the Gilmore
and Milne [57] study ranged from $15,509 to $19,281
when considering the short-and medium-term benefits of
MPH. The authors note that evidence of cost-effectiveness
beyond 6 months is poorer, and it is uncertain whether
the effects of MPH persist into adolescence and
adulthood. In the Novartis study, the cost per QALY
gained was $27,766.
CONCLUSIONS AND RECOMMENDATIONS 
FOR FUTURE RESEARCH
A growing body of literature has demonstrated that
ADHD places a substantial economic burden on patients,
families, and third-party payers. However, all available
published studies on the economic implications of
ADHD are relatively recent, and there are many additional
questions to be examined in future research. Thus far,
studies have identified several aspects of ADHD that are
likely to have economic implications, including direct
treatment costs, increased rates of comorbid psychiatric
disorders, high accident rates, work loss, and criminality.
There are many other well-documented outcomes of
ADHD that are likely to have economic implications. For
example, ADHD frequently has detrimental effects on a
child's academic performance and behavior in school.
These difficulties are likely to place an economic burden
on school systems, as there is an increased need for
school-based services such as in-school medication
administration; special education services; child and pos-
sibly parent counseling; educational testing; development
of individualized educational programs; and efforts to
address disruptive classroom behaviors [65,66]. Research
is needed to quantify these costs and identify strategies for
implementing the most cost-effective services. Further-
more, it is well known that adults with ADHD tend to
have poor driving records and relatively high rates of traf-
fic accidents [14,15,34]. These driving problems are also
likely to present a significant cost which is not yet been
examined.
The international literature on cost of ADHD could also
be expanded. Nearly all published studies identified for
the current review were conducted in the US. Given inter-
national differences in medical care systems and practice
patterns, it is difficult to apply the direct treatment costs
from US studies to countries outside the US. It is likely,
however, that the indirect cost burden of ADHD identi-
fied in US studies may be similar to the burden in other
countries, although it may not be recognized to the same
extent. Recognition, diagnosis, and treatment of ADHD
Table 2: Studies of the Cost-Effectiveness of Treatment for ADHD
Citation Comparators Study Design Findings1
Gilmore & Milne 2001 MPH, placebo • Decision analytic model assessing 
cost-utility
Cost per each additional QALY gained with MPH 
treatment (versus no treatment) ranged from 
$15,509 to $19,281 when considering short-and 
medium-term benefits of MPH. Cost per QALY 
gained ranged from $9,850–$59,101 in sensitivity 
analyses
Novartis data on file (2000; 
referenced in Lord & Paisley 2000)
MPH, placebo • Decision analytic model assessing 
cost-utility
Cost per each additional QALY gained with MPH 
treatment (versus no treatment) was $27,766.
Zupancic et al. 1998 MPH, placebo • Decision analytic model assessing 
cost-effectiveness
Cost per each additional point in the Conners 
Teacher Rating Scale gained with MPH treatment 
(versus no treatment) was $93, or $560 for a 6-
point (1 SD) gain.
1All costs updated to Year 2004 US $ using the Medical Services component of the Consumer Price Index (for US-based studies). For non-US 
studies, all country-specific costs first updated to Year 2004 currency values based on country-specific inflators; and then converted to Year 2004 
US$ based on currency exchange rates.
MPH = methylphenidate
QALY = quality-adjusted life yearsCost Effectiveness and Resource Allocation 2005, 3:5 http://www.resource-allocation.com/content/3/1/5
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are increasing in Europe and Australia, and future studies
may document the economic burden of ADHD in these
areas.
Finally, more work is needed on determining the poten-
tial cost-effectiveness of the various treatment options for
ADHD. The initial research on cost-effectiveness of treat-
ment has focused on MPH, and results generally indicate
that treatment of ADHD is cost-effective. As new treat-
ments are introduced (e.g., the new non-stimulant atom-
oxetine), it is important to evaluate their cost-effectiveness
to provide an indication of their potential value to clini-
cians, patients, families, and third-party payers. Effective
treatments, while possibly increasing direct medical costs,
are likely to reduce the overall burden of ADHD by con-
trolling symptoms, improving children's functioning, and
substantially reducing indirect costs to families.
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